"Real-world" effectiveness of daily controller medicine in children with mild persistent asthma (Q44458872)

3 December 2017

"Real-world" effectiveness of daily controller medicine in children with mild persistent asthma (English)

1 reference

3 December 2017

0 references

Don A Bukstein

1

1 reference

PubMed ID

12775136

3 December 2017

Allan T Luskin

series ordinal

2

1 reference

PubMed ID

12775136

3 December 2017

Avi Bernstein

series ordinal

3

1 reference

3 December 2017

1 May 2003

1 reference

Annals of Allergy, Asthma & Immunology

3 December 2017

1 reference

3 December 2017

90

1 reference

3 December 2017

5

1 reference

3 December 2017

543-549

1 reference

A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

Pediatric asthma deaths in Victoria: the mild are at risk

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

Nonadherence in asthmatic patients: is there a solution to the problem?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

Noncompliance and treatment failure in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

The complexity of treatment adherence in adults with asthma: challenges and opportunities.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961848-0

7 January 2021

10.1016/S1081-1206(10)61848-0

Identifiers

DOI

1 reference

3 December 2017

1 reference

PubMed ID

12775136